echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Baiji Shenzhou and Xinji company have reached strategic cooperation in the field of immune tumor and jointly developed PD-1 monoclonal antibody

    Baiji Shenzhou and Xinji company have reached strategic cooperation in the field of immune tumor and jointly developed PD-1 monoclonal antibody

    • Last Update: 2017-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Yaodu Toutiao 2017-07-07 beigene, a biopharmaceutical company dedicated to molecular targeting and immunotumor research, announced on July 5, 2017 that its PD-1 inhibitor bgb-a317 has entered a critical clinical trial stage Bgb-a317 is an immunosuppressant developed by Baiji Shenzhou for the treatment of bladder cancer This clinical trial is aimed at patients with advanced or metastatic bladder cancer who have positive expression of PD-L1 and are in the early stage of treatment At the same time, the study of bgb-a317 in the treatment of relapsed or refractory classical Hodgkin's lymphoma is also in a critical stage In addition, beigene has chosen to enter into a strategic partnership with celgene, a pharmaceutical giant, to jointly develop bgb-a317 As a drug product with great potential to become the best in class for solid tumor treatment, bgb-a317 will expand the product chain of the new base The new bgb-a317 can be authorized by other regions except Asia to accelerate the strategic deployment of the new bgb-a317 in the field of immune tumor, and more in-depth research on bgb-a317 will be carried out in 2018 In this cooperation, Baiji Shenzhou will obtain exclusive authorization from Xinji to sell Abraxane ® paclitaxel for injection (albumin binding type), Revlimid ® (lenalidomide; the drug is expected to become the second in global sales in 2022), vidaza ® (azacytidine) and advance payment of about US $263 million in China In addition, Xinji will purchase 32.7 million or 5.9% common shares of Baiji Shenzhou for $4.58 per share The price of US $59.55 per share is equivalent to a 35% premium to the volume weighted average price of American Depository Receipts in the previous 11 trading days in baichi Baiji Shenzhou can receive up to $980 million in payments (including R & D, registration and sales) and bgb-a317 sales royalties The deal has been approved by the board of directors of SUNKEY and Baiji Both parties are expected to complete this transaction in the third quarter of 2017, and the specific completion time will depend on the expiration or termination of the waiting period specified in other applicable provisions such as the anti-monopoly law "For Xinji, this cooperation will speed up our research on the development of 'immunocheckpoint' inhibitors in the field of solid tumors Similarly, the results of this project will also be applied to the field of PD-L1 fusion in the field of new blood system malignant tumors Gamma On the project Xinji regards China as a very important market Through cooperation with Baiji Shenzhou, we will improve our research and production processes in China, and at the same time, deeply tap the market potential " Said Mark J alles, CEO of newbase John v oyler, CEO and founder of Baiji Shenzhou company, said: "in China, there are about 55000 to 80000 new bladder cancer patients every year Among them, the bladder cancer patients with ineffective chemotherapy cannot get effective treatment, and the effect of the existing scheme is not good After realizing the demands of patients, we decided to develop bgb-a317 to meet the needs of patients, and look forward to a broader clinical trial in China In terms of strategic cooperation with Xinji, given that a certain number of potential drugs of Baiji Shenzhou are in the critical stage of trial in China, we believe that with this important transformation opportunity, we can help Baiji Shenzhou to become a commercial company, and the successful transformation of the company can pave the way for subsequent product listing Such cooperation is in the interests of both parties In the future, the two companies will We will work together to provide more treatment options for patients in China and even in the world " "Bgb-a317 is a PD-1 inhibitor developed by the company In this round of clinical trials, we will mainly investigate the effectiveness and safety of bgb-a317," said Amy Peterson, M.D., chief medical officer of Baiji Shenzhou On this basis, we will also expand the scope of clinical trials in China and other regions, and there are various forms, including bgb-a317 single administration, bgb-a317 combined administration and other ways Professor Ding Weiye from Shanghai Cancer Center of Fudan University was in charge of the clinical trial, which mainly evaluated the safety and effectiveness of bgb-a317 in the treatment of patients with advanced or metastatic bladder cancer with PD-L1 positive expression and in the early stage of treatment In this study, the independent evaluation group evaluated the overall response rate of bgb-a317 according to the response evaluation criteria in solid tumors version 1.1 The secondary focus was to assess the response duration, disease control rate, progression free survival, total survival, safety and tolerability of bgb-a317 during treatment Bgb-a317 bgb-a317 is an immunosuppressive checkpoint inhibitor It is a human monoclonal antibody It can specifically bind with PD-1 receptor on the surface of immune T-cells, release the inhibition on T-cells, and achieve the anti-tumor effect by restoring the normal operation of the immune system Bgb-a317 is different from PD-1 drugs on the market Bgb-a317 is designed to specifically bind to Fc gamma receptor Molecular targeting agents: Based on the specific expression of tumor cells at different stages, there are three clinical research projects in Baiji Shenzhou, including bgb-3111, Btk inhibitor, bgb-283 RAF inhibitor, and EGFR inhibitory activity Bgb-290 has high activity of PARP1 / 2 inhibitor Immunotumor therapy: it not only uses the immune system to treat diseases, but also mainly studies bgb-a317, a PD-1 inhibitor Combined therapy: targeted cancer treatment blocks the biochemical pathway or mutant protein necessary for tumor cell growth and survival Historically, targeted therapy can inhibit tumor progression and induce tumor death, so as to obtain a high anti-tumor response rate Because of the complexity of immune cells in tumor progression, targeted therapy can not hinder the mechanism of anti-tumor immunity in all patients Therefore, the combination of immunotherapy and targeted tumor therapy can provide a better treatment in theory At present, there are three groups of combination therapy in the research stage in Baiji: bgb-3111 and obinutuzumab (gazyva) to treat mantle cell lymphoma Bgb-a317 is combined with bgb-290 for the treatment of breast cancer Bgb-a317 and bgb-3111 were used in the treatment of lymphomas.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.